Non-cisgender assigned female at birth (AFAB) patients who have received testosterone therapy have an increased risk for acne and androgenetic alopecia, and non-cisgender assigned male at birth (AMAB) patients are significantly more likely to undergo minimally invasive procedures, according to study research published in the Journal of the American Academy of Dermatology.

Investigators conducted a retrospective chart review of all transgender patients who were evaluated at the Mayo Clinic in Rochester, Minnesota, from March 15, 1986, to June 21, 2018. A total of 442 cases met the study inclusion criteria, and of this group 214 patients (48.4%) had dermatologic diagnoses and/or procedures.